RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q1 FY25 results · Apr–Jun 2024
RPG Life Sciences reported revenue from operations of ₹165.42 crore (up 11.9% from Q1 FY24) and net profit of ₹26.76 crore (up 21.1% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a standalone basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 165.42 | 147.78 | +11.9% | 126.99 | +30.3% |
| Other income | 2.37 | 1.81 | +30.9% | 1.65 | +43.6% |
| Total income | 167.79 | 149.59 | +12.2% | 128.64 | +30.4% |
| Profit before tax | 36.00 | 29.77 | +20.9% | 17.74 | +102.9% |
| Net profit for the period | 26.76 | 22.10 | +21.1% | 13.24 | +102.1% |
| EPS, basic (₹) | 16.18 | 13.36 | +21.1% | 8.01 | +102.0% |
| Net margin (%) | 16.2 | 15.0 | 10.4 |
Standalone
- Filed with BSE
- 20 Aug 2024, 12:27 IST
- Board meeting
- 19 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE